{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:30:38Z","timestamp":1788535838275,"version":"build-2803163510"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-eoi240005-4\"><jats:title>Importance<\/jats:title><jats:p>Diabetic retinopathy (DR) is a leading cause of blindness in the US, warranting updates on its prevalence and incidence in the setting of advancements in diabetic care over recent years.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240005-5\"><jats:title>Objective<\/jats:title><jats:p>To determine recent trends in DR prevalence stratified by baseline demographics to identify those populations at greater risk.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240005-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a cross-sectional epidemiologic evaluation conducted using deidentified data from the large federated TriNetX Analytics health research network composed of 56 health care organizations in the US. Patients from 2015 to 2022 who had an <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision <\/jats:italic>code of type 1 DR (T1DR) or type 2 DR (T2DR) were included in this analysis. Patients were further stratified by age cohorts (20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70 years or older), race and ethnicity, and sex.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240005-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Prevalence per 100\u202f000 patients and prevalence odds ratios (ORs) were calculated in Microsoft Excel and Posit (formerly RStudio).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240005-8\"><jats:title>Results<\/jats:title><jats:p>A total of 359\u202f126 patients with T1DR or T2DR (mean [SD] age, 67 [14] years; 52% female) were included in this study between January 1, 2015, and December 21, 2022. T1DR increased in prevalence from 2015 to 2022, with T1DR increasing 1.15-fold affecting 70.4 patients per 100\u202f000 in 2022. T2DR increased 1.07-fold affecting 461.7 patients per 100\u202f000 in 2022. For T1DR, the cohort aged 20 to 39 years had the most substantial increase at 4.7 and 1.96 fold. Overall, White males had the largest prevalence ORs of T1DR at 1.41 (95% CI, 1.36-1.47) compared with White females (reference group). In T2DR, patients aged 20 to 39 years again had a 2.5- and 1.6-fold prevalence increase from 2015 to 2022. Regardless of age group, Hispanic males demonstrated larger prevalence OR at 4.08 (95% CI, 3.97-4.19) compared with White females followed by Hispanic females at 2.49 (95% CI, 2.42-2.56), Black males at 2.23 (95% CI, 2.17-2.29), and Black females at 2.00 (95% CI, 1.95-2.05).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240005-9\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>The prevalence of both T1DR and T2DR increased in this network from 2015 to 2022, with individuals aged 20 to 39 years showing large increases. Additionally, T2DR was associated with greater increases in both Hispanic and Black communities. These findings support DR screening in young adults and for T2DR interventions specifically designed for racial and ethnic minoritized patients most affected by disease. Future investigations are warranted to further investigate these trends among young adults.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.0046","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:23:10Z","timestamp":1718292190000},"page":"599","source":"Crossref","is-referenced-by-count":27,"title":["Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network"],"prefix":"10.1001","volume":"142","author":[{"given":"Jonathan","family":"Markle","sequence":"first","affiliation":[{"name":"Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K.","family":"Shaia","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harman","family":"Araich","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio"},{"name":"Cleveland Clinic Martin Hospitals, Martin, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9735","key":"eoi240005r1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy.","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"eoi240005r2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/dme.v37.6","article-title":"Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications.","volume":"37","author":"Middleton","year":"2020","journal-title":"Diabet Med"},{"issue":"10","key":"eoi240005r3","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.2337\/dc08-0580","article-title":"Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors.","volume":"31","author":"Wong","year":"2008","journal-title":"Diabetes Care"},{"issue":"1","key":"eoi240005r4","doi-asserted-by":"publisher","first-page":"38113","DOI":"10.1038\/srep38113","article-title":"Diabetes onset at 31-45 years of age is associated with an increased risk of diabetic retinopathy in type 2 diabetes.","volume":"6","author":"Zou","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"eoi240005r5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.17352\/ijcem","article-title":"Diabetic retinopathy: focus on minority populations.","volume":"3","author":"Barsegian","year":"2017","journal-title":"Int J Clin Endocrinol Metab"},{"issue":"2","key":"eoi240005r6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jnma.2021.12.011","article-title":"Racial disparities in the screening and treatment of diabetic retinopathy.","volume":"114","author":"Coney","year":"2022","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"eoi240005r7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035.","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"eoi240005r9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.2337\/diacare.24.7.1204","article-title":"Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER.","volume":"24","author":"West","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"eoi240005r10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ajo.2005.08.063","article-title":"Diabetic retinopathy in a multiethnic cohort in the US.","volume":"141","author":"Wong","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi240005r11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ophtha.2004.03.002","article-title":"Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study.","volume":"111","author":"Varma","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi240005r12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the US, 2005-2008.","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"eoi240005r13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021.","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240005r14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","article-title":"Trends in prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among Medicare part b fee-for-service beneficiaries.","volume":"140","author":"Lundeen","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240005r15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/archopht.122.4.546","article-title":"The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the US.","volume":"122","author":"Roy","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"eoi240005r16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.18043\/ncm.80.2.76","article-title":"Trends and racial\/ethnic disparities in diabetic retinopathy among adults with diagnosed diabetes in North Carolina, 2000-2015.","volume":"80","author":"Luo","year":"2019","journal-title":"N C Med J"},{"issue":"6","key":"eoi240005r17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/09286580802435179","article-title":"Prevalence and risk factors of diabetic retinopathy in a multiracial underserved population.","volume":"15","author":"Lim","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"issue":"8","key":"eoi240005r18","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2337\/diacare.28.8.1954","article-title":"Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial.","volume":"28","author":"Emanuele","year":"2005","journal-title":"Diabetes Care"},{"issue":"24","key":"eoi240005r22","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1001\/jama.2019.19365","article-title":"Prevalence of diabetes by race and ethnicity in the US, 2011-2016.","volume":"322","author":"Cheng","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"eoi240005r23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S2213-8587(23)00025-6","article-title":"Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based search for Diabetes in Youth study.","volume":"11","author":"Wagenknecht","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"eoi240005r24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ije\/dyz273","article-title":"Has the prevalence of overweight, obesity, and central obesity levelled off in the US\u2014trends, patterns, disparities, and future projections for the obesity epidemic.","volume":"49","author":"Wang","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"7","key":"eoi240005r25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/dc19-1988","article-title":"Adolescent obesity and early-onset type 2 diabetes.","volume":"43","author":"Twig","year":"2020","journal-title":"Diabetes Care"},{"key":"eoi240005r26","doi-asserted-by":"publisher","first-page":"n2332","DOI":"10.1136\/bmj.n2332","article-title":"Obesity in US children increased at an unprecedented rate during the pandemic.","volume":"374","author":"Dyer","year":"2021","journal-title":"BMJ"},{"issue":"6 suppl","key":"eoi240005r27","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.ajo.2011.08.045","article-title":"Vision health disparities in the US by race\/ethnicity, education, and economic status: findings from 2 nationally representative surveys.","volume":"154","author":"Zhang","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi240005r28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archopht.123.3.387","article-title":"Perceived barriers to diabetic eye care: qualitative study of patients and physicians.","volume":"123","author":"Hartnett","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi240005r29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0027-9684(15)30929-9","article-title":"Disparities in diabetic retinopathy screening and disease for racial and ethnic minority populations\u2014a literature review.","volume":"101","author":"Nsiah-Kumi","year":"2009","journal-title":"J Natl Med Assoc"},{"key":"eoi240005r8","unstructured":"American Diabetes Association. New American Diabetes Association report finds annual costs of diabetes to be $412.9 billion. Accessed July 16, 2023. https:\/\/diabetes.org\/about-us\/statistics\/cost-diabetes"},{"key":"eoi240005r19","unstructured":"US Census Bureau. Quick facts US. Accessed July 28, 2023. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/IPE120221"},{"key":"eoi240005r20","unstructured":"US Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed December 17, 2023. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html"},{"key":"eoi240005r21","unstructured":"US Centers for Disease Control and Prevention. Appendix. Accessed December 17, 2023. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/appendix.html#appendix-b"},{"key":"eoi240005r30","unstructured":"North Carolina Department of Health and Human Services. For local health departments. Accessed August 7, 2023. https:\/\/www.dph.ncdhhs.gov\/local-health-departments"},{"key":"eoi240005r31","unstructured":"American Academy of Ophthalmology. ICD-10 diagnosis code for 250.03 type 1 diabetes mellitus, juvenile, uncontrolled? Accessed August 7, 2023. https:\/\/www.aao.org\/practice-management\/news-detail\/icd-10-diagnosis-code-250-03-type-1-diabetes-melli"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2819933\/jamaophthalmology_markle_2024_oi_240005_1719935966.55625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:03:51Z","timestamp":1721315031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2819933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.0046","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}